UPDATE: JMP Reiterates Market Perform on BioCryst Pharmaceuticals, Places TP Under Review Awaiting Details

In a report published Monday, JMP Securities analyst Liisa Bayko reiterated Market Perform on BioCryst Pharmaceuticals, Inc.

, placing target price under review while awaiting details on upcoming programs that could affect it. According to the report, “BCRX provided an update on data flow from its HAE program, including data presentations on kallikrein inhibitor, BCX4161, at AAAAI in late February/early March and data from the 28-day proof-of-concept study in 1H14, which we view as a key value driver for the company. BioCryst has also profiled its second generation kallikrein inhibitors, which have the expected benefits of better bio-availability (at least 5x BCX4161) and selectivity (at least 4x more selective against tissue factor VII). We anticipate that one of these compounds will move into human development in 1H15. BioCryst is also planning to leverage its drug discovery efforts into a second orphan disease in 2H14. We recommend shares of BioCryst into potentially transformative Phase 2a data.” BCRX closed Friday at $9.99.